£2.68M Award to NRG Therapeutics Supports Work Into Potential DMT
NRG Therapeutics has received a £2.68M (about $3.4 million) award to support preclinical work into small molecule disease-modifying therapies for neurodegenerative conditions such as Parkinson’s disease. The two-year Biomedical Catalyst award given the company is for early stage research in treatments to protect mitochondria in the brain, and is partly funded…